Authors
Yunqi Jiang, Sai Zhang, Sharareh Arami
Published in
Annals of hematology. Volume 105. Issue 12. Aug 15, 2026. Epub Aug 15, 2026.
Abstract
Adoptive cellular immunotherapy has transformed the treatment landscape for hematologic malignancies; however, its broader application to solid tumors remains limited by antigen heterogeneity, inadequate persistence, restricted tumor infiltration, and the profoundly immunosuppressive tumor microenvironment (TME). While conventional CAR-T cell therapy has demonstrated remarkable clinical success, no single immune-cell platform is likely to overcome all biological barriers encountered in complex solid tumors. Emerging evidence instead supports a shift toward an integrated cellular immunotherapy ecosystem that combines the complementary strengths of multiple engineered immune cell populations. In this review, we present a unifying framework for the multi-layered engineering of next-generation immune cell therapies, encompassing CAR-natural killer (CAR-NK) cells, TCR-engineered αβ T cells, γδ T cells, CAR-natural killer T (CAR-NKT) cells, and CAR-macrophages. Rather than considering these platforms as isolated technologies, we examine how shared engineering strategies, including cytokine armoring, CRISPR-based genome editing, protein-level receptor optimization, tumor-responsive gene circuits, metabolic reprogramming, and induced pluripotent stem cell (iPSC)-based manufacturing, can be integrated to enhance persistence, functionality, safety, and resistance to TME-mediated suppression. We further discuss the biological rationale, preclinical advances, and emerging clinical evidence supporting each platform, highlighting their distinct and complementary mechanisms of tumor recognition and immune activation. Finally, we propose that the future of cancer immunotherapy lies not in the optimization of a single cellular modality, but in the development of synergistic, scalable, and off-the-shelf engineered immune-cell networks capable of delivering durable and effective responses against heterogeneous solid tumors.
PMID:
43013134
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0